Document › Details
Bayer AG. (5/5/15). "Press Release: Bayer CropScience and Flagship Ventures Form Strategic Innovation Partnership to Fund Leading-edge Agriculture Ventures". Monheim.
Boosting innovation capacities through venture capital and strategic collaborations
Striving to push the bounds of agricultural innovation, Bayer CropScience today announced a strategic innovation partnership with Flagship Ventures, a leading venture capital and venture creation firm. The partnership also includes an investment in Flagship Ventures Fund V, a $537 million venture capital fund that closed in March 2015. Bayer CropScience brings its strengths in science, innovation and regulatory affairs to help Flagship to identify, fund, and develop startup companies exploring new frontiers in agriculture.
“Emerging challenges in agriculture are leading the industry in new and exciting directions,” said Liam Condon, Chief Executive Officer of Bayer CropScience. “With growing pest pressures, weather volatility and changes in consumer tastes, growers need and are counting on new solutions to increase yields on the farm. Bayer is committed to providing them with new innovations. We look forward to working with Flagship Ventures to bring exciting, breakthrough companies to market.”
Bayer CropScience joins AstraZeneca and Nestlé Health Science as strategic innovation partners in Flagship Ventures Fund V. The fund will focus on innovations in healthcare and sustainability in the energy, water, agriculture and nutrition sectors. Financial terms were not disclosed.
“Partnering with Bayer CropScience will help us realize the emerging opportunity we see for the development of game-changing technologies in agriculture,” said Dr. Noubar Afeyan, Senior Managing Partner and Chief Executive Officer of Flagship Ventures. “Collectively we are dedicated to making sustainable, positive impacts on global farm operations and the global food supply.”
Bayer CropScience invests heavily in research and development in areas such as breeding, trait development, biologics and small molecules. Collaborating with venture capital firms offers insights into new areas of innovation and visibility to cutting-edge technologies.
“We must improve food production to feed a growing planet and are looking for ways to gain access to new technologies,” said Geoff Kneen, Bayer CropScience R&D Licensing and New Ventures Manager for North America. “As the interest in agriculture rapidly expands to include different areas of innovation, such as genomics, IT/data management, and remote sensing, we want a window into that new innovation. Flagship shares our vision for solving some of the challenges facing modern production agriculture.”
About Bayer CropScience
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer CropScience, the subgroup of Bayer AG responsible for the agricultural business, has annual sales of EUR 9,494 million (2014) and is one of the world’s leading innovative crop science companies in the areas of seeds, crop protection and non-agricultural pest control. The company offers an outstanding range of products including high value seeds, innovative crop protection solutions based on chemical and biological modes of action as well as an extensive service backup for modern, sustainable agriculture. In the area of non-agricultural applications, Bayer CropScience has a broad portfolio of products and services to control pests from home and garden to forestry applications. The company has a global workforce of 23,100 and is represented in more than 120 countries. This and further news is available at: www.press.bayercropscience.com.
About Flagship Ventures
Realizing entrepreneurial innovation is the mission of Flagship Ventures. Founded in 2000, the firm has launched 30 companies while investing in another 50. Flagship manages $1.4 billion in capital and is active in three principal sectors: therapeutics, health technologies, and sustainability. Flagship’s current portfolio includes Acceleron (NASDAQ: XLRN), Agios (NASDAQ: AGIO), BIND Therapeutics (NASDAQ: BIND), Concert Pharmaceuticals (NASDAQ: CNCE), Eleven Biotherapeutics (NASDAQ: EBIO), T2 Biosystems (NASDAQ: TTOO), Tetraphase (NASDAQ: TTPH) as well as several private companies: Editas Medicine, Pronutria Biosciences, Seres Health and Moderna Therapeutics. For more information, please visit www.flagshipventures.com.
About Flagship VentureLabs
Flagship VentureLabs™ is the innovation foundry of Flagship Ventures. VentureLabs has been creating breakthrough companies since 2000. It is the first institution dedicated to entrepreneurial innovation, where the acts of discovery, invention and entrepreneuring are performed simultaneously by a world-class team of scientists, innovators and professional entrepreneurs. VentureLabs innovates, invents, launches and builds startups through a unique, systematic approach that produces best-in-class companies. VentureLabs has started 30 life science and technology companies, including Seres Health, Pronutria Biosciences and Moderna Therapeutics. For more information, please visit www.flagshipventures.com/venturelabs.
For more information on Bayer CropScience visit www.bayercropscience.com
or join the conversation @Bayer4Crops.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Record changed: 2017-04-02
More documents for Bayer (Group)
-  Icagen, Inc.. (3/28/17). "Press Release: Icagen Announces Collaboration with Bayer to Develop Novel XRpro Assays". Durham, NC....
-  CRISPR Therapeutics AG. (3/14/17). "Press Release: CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte". Basel, Cambridge, MA & Gaithersburg, MD....
-  Bayer AG. (2/22/17). "Press Release: Financial News Conference. Address by Johannes Dietsch –Member of the Board of Management". Leverkusen....
-  Bayer AG. (2/22/17). "Press Release: Financial News Conference. Address by Werner Baumann –Chairman of the Board of Management". Leverkusen....
-  Bayer AG. (2/22/17). "Press Release: Fiscal 2016. Another Record Year for Bayer – Good Progress with the Acquisition of Monsanto". Leverkusen....
-  Bayer AG. (2/21/17). "Press Release: Bayer Proposes Increased Dividend for 2016 of EUR 2.70 per Share. Total Dividend Payout Rises 8 Percent to EUR 2,233 Million". Leverkusen....
-  Bayer AG. (2/20/17). "Press Release: Farmers Set to Benefit from Technology License Agreement between Bayer and Yara". Oslo & Monheim....
-  Bayer AG. (2/15/17). "Press Release: Bayer to Showcase Xofigo Prostate Cancer Data at ASCO GU 2017 [Not intended for U.S. and UK Media]". Berlin....
-  Compugen Ltd.. (2/15/17). "Press Release: Compugen Reports Fourth Quarter and Calendar Year 2016 Results". Holon....
-  Bayer AG. (2/8/17). "Press Release: Phase III COMPASS study with Bayer’s Rivaroxaban in Patients with Coronary or Peripheral Artery Disease Shows Overwhelming Efficacy and Meets Primary Endpoint Early ". Berlin....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)